1py5 › Citations

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM
Bioorg Med Chem Lett 14 3581-4 (2004)
Cited: 82 times
EuropePMC logo PMID: 15177479

Abstract

We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

Reviews - 1py5 mentioned but not cited (1)

  1. Substrate and docking interactions in serine/threonine protein kinases. Goldsmith EJ, Akella R, Min X, Zhou T, Humphreys JM. Chem Rev 107 5065-5081 (2007)

Articles - 1py5 mentioned but not cited (18)

  1. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Bocciardi R, Bordo D, Di Duca M, Di Rocco M, Ravazzolo R. Eur J Hum Genet 17 311-318 (2009)
  2. Structural basis for specificity of TGFβ family receptor small molecule inhibitors. Ogunjimi AA, Zeqiraj E, Ceccarelli DF, Sicheri F, Wrana JL, David L. Cell Signal 24 476-483 (2012)
  3. ALK2 mutation in a patient with Down's syndrome and a congenital heart defect. Joziasse IC, Smith KA, Chocron S, van Dinther M, Guryev V, van de Smagt JJ, Cuppen E, Ten Dijke P, Mulder BJ, Maslen CL, Reshey B, Doevendans PA, Bakkers J. Eur J Hum Genet 19 389-393 (2011)
  4. Luteolin Inhibits Vascular Smooth Muscle Cell Proliferation and Migration by Inhibiting TGFBR1 Signaling. Wu YT, Chen L, Tan ZB, Fan HJ, Xie LP, Zhang WT, Chen HM, Li J, Liu B, Zhou YC. Front Pharmacol 9 1059 (2018)
  5. A comparative reverse docking strategy to identify potential antineoplastic targets of tea functional components and binding mode. Zheng R, Chen TS, Lu T. Int J Mol Sci 12 5200-5212 (2011)
  6. Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. Guven-Maiorov E, Acuner-Ozbabacan SE, Keskin O, Gursoy A, Nussinov R. Cancers (Basel) 6 663-683 (2014)
  7. Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas. Comes Franchini M, Bonini BF, Camaggi CM, Gentili D, Pession A, Rani M, Strocchi E. Eur J Med Chem 45 2024-2033 (2010)
  8. Docking-based virtual screening of TβR1 inhibitors: evaluation of pose prediction and scoring functions. Wang S, Jiang JH, Li RY, Deng P. BMC Chem 14 52 (2020)
  9. Network Pharmacology and Experimental Assessment to Explore the Pharmacological Mechanism of Qimai Feiluoping Decoction Against Pulmonary Fibrosis. Yang Y, Ding L, Bao T, Li Y, Ma J, Li Q, Gao Z, Song S, Wang J, Zhao J, Wang Z, Zhao D, Li X, Wang Z, Zhao L, Tong X. Front Pharmacol 12 770197 (2021)
  10. Discovery of New Inhibitors of Transforming Growth Factor-Beta Type 1 Receptor by Utilizing Docking and Structure-Activity Relationship Analysis. Jiang JH, Deng P. Int J Mol Sci 20 E4090 (2019)
  11. Novel Transforming Growth Factor-Beta Receptor 1 Antagonists through a Pharmacophore-Based Virtual Screening Approach. Jiang J, Zhou H, Jiang Q, Sun L, Deng P. Molecules 23 E2824 (2018)
  12. Cordifolioside: potent inhibitor against Mpro of SARS-CoV-2 and immunomodulatory through human TGF-β and TNF-α. Manne M, Goudar G, Varikasuvu SR, Khetagoudar MC, Kanipakam H, Natarajan P, Ummiti MD, Yenagi VA, Chinthakindi S, Dharani P, Thota DSS, Patil S, Patil V. 3 Biotech 11 136 (2021)
  13. Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors. Araujo SC, Maltarollo VG, Almeida MO, Ferreira LLG, Andricopulo AD, Honorio KM. Molecules 25 E264 (2020)
  14. Momordica charantia silver nanoparticles modulate SOCS/JAK/STAT and P13K/Akt/PTEN signalling pathways in the kidney of streptozotocin-induced diabetic rats. Elekofehinti OO, Oyedokun VO, Iwaloye O, Lawal AO, Ejelonu OC. J Diabetes Metab Disord 20 245-260 (2021)
  15. Investigation of the Effects of Glabridin on the Proliferation, Apoptosis, and Migration of the Human Colon Cancer Cell Lines SW480 and SW620 and Its Mechanism Based on Reverse Virtual Screening and Proteomics. Li T, Li H, Xia W, Li M, Niu Y, Fu X. Oxid Med Cell Longev 2023 1117431 (2023)
  16. Pharmacophore mapping approach to find anti-cancer phytochemicals with metformin-like activities against transforming growth factor (TGF)-beta receptor I kinase: An in silico study. Reza R, Morshed N, Samdani MN, Reza MS. PLoS One 18 e0288208 (2023)
  17. Rapid Identification of Inhibitors and Prediction of Ligand Selectivity for Multiple Proteins: Application to Protein Kinases. Ma Z, Huang SY, Cheng F, Zou X. J Phys Chem B 125 2288-2298 (2021)
  18. Structure-Guide Design and Optimization of Potential Druglikeness Inhibitors for TGFβRI with the Pyrrolopyrimidine Scaffold. Meng D, Xie J, Li Y, Li R, Zhou H, Deng P. Pharmaceuticals (Basel) 15 1264 (2022)


Reviews citing this publication (20)

  1. The polarization of immune cells in the tumour environment by TGFbeta. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. Nat Rev Immunol 10 554-567 (2010)
  2. Development of TGF-beta signalling inhibitors for cancer therapy. Yingling JM, Blanchard KL, Sawyer JS. Nat Rev Drug Discov 3 1011-1022 (2004)
  3. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM. Drug Des Devel Ther 9 4479-4499 (2015)
  4. A review on anticancer potential of bioactive heterocycle quinoline. Afzal O, Kumar S, Haider MR, Ali MR, Kumar R, Jaggi M, Bawa S. Eur J Med Chem 97 871-910 (2015)
  5. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Tan AR, Alexe G, Reiss M. Breast Cancer Res Treat 115 453-495 (2009)
  6. A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment. Huynh LK, Hipolito CJ, Ten Dijke P. Biomolecules 9 E743 (2019)
  7. Inhibiting TGF-β signaling in hepatocellular carcinoma. Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Biochim Biophys Acta 1815 214-223 (2011)
  8. Role of transforming growth factor-beta in cancer progression. Galliher AJ, Neil JR, Schiemann WP. Future Oncol 2 743-763 (2006)
  9. TGF-beta inhibitors for the treatment of cancer. Lahn M, Kloeker S, Berry BS. Expert Opin Investig Drugs 14 629-643 (2005)
  10. Choosing between stem cell therapy and drugs in myelofibrosis. Kröger N, Mesa RA. Leukemia 22 474-486 (2008)
  11. Strategies for TGF-beta modulation: a review of recent patents. Bonafoux D, Lee WC. Expert Opin Ther Pat 19 1759-1769 (2009)
  12. Transforming growth factor-beta: a target for cancer therapy. Kelly RJ, Morris JC. J Immunotoxicol 7 15-26 (2010)
  13. Proteins mediating collagen biosynthesis and accumulation in arterial repair: novel targets for anti-restenosis therapy. Osherov AB, Gotha L, Cheema AN, Qiang B, Strauss BH. Cardiovasc Res 91 16-26 (2011)
  14. TGF-β signaling pathway as a pharmacological target in liver diseases. Zhang S, Sun WY, Wu JJ, Wei W. Pharmacol Res 85 15-22 (2014)
  15. Structural biology of the TGFβ family. Goebel EJ, Hart KN, McCoy JC, Thompson TB. Exp Biol Med (Maywood) 244 1530-1546 (2019)
  16. TGFβ-Directed Therapeutics: 2020. Teicher BA. Pharmacol Ther 217 107666 (2021)
  17. Current and emerging drugs for idiopathic pulmonary fibrosis. Gharaee-Kermani M, Hu B, Thannickal VJ, Phan SH, Gyetko MR. Expert Opin Emerg Drugs 12 627-646 (2007)
  18. Emerging drugs for idiopathic pulmonary fibrosis. Thannickal VJ, Flaherty KR, Hyzy RC, Lynch JP. Expert Opin Emerg Drugs 10 707-727 (2005)
  19. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Mesa RA, Quintás-Cardama A, Verstovsek S. Curr Hematol Malig Rep 2 25-33 (2007)
  20. Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives. Ardevines S, Marqués-López E, Herrera RP. Curr Med Chem 30 1145-1174 (2023)

Articles citing this publication (43)

  1. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Bioorg Med Chem Lett 18 4388-4392 (2008)
  2. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. Yi JY, Shin I, Arteaga CL. J Biol Chem 280 10870-10876 (2005)
  3. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF. Eur J Cancer 44 142-150 (2008)
  4. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Mol Cell Biol 28 5605-5620 (2008)
  5. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Rodon J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Clin Cancer Res 21 553-560 (2015)
  6. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Oncogene 25 3408-3423 (2006)
  7. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, Das G, Kumar D, Rao KV. PLoS Pathog 6 e1000839 (2010)
  8. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. Akool el-S, Doller A, Babelova A, Tsalastra W, Moreth K, Schaefer L, Pfeilschifter J, Eberhardt W. J Immunol 181 2831-2845 (2008)
  9. TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Buijs JT, Stayrook KR, Guise TA. Cancer Microenviron 4 261-281 (2011)
  10. Functional modeling of the ACVR1 (R206H) mutation in FOP. Groppe JC, Shore EM, Kaplan FS. Clin Orthop Relat Res 462 87-92 (2007)
  11. Directing differentiation of human embryonic stem cells toward anterior neural ectoderm using small molecules. Surmacz B, Fox H, Gutteridge A, Fish P, Lubitz S, Whiting P. Stem Cells 30 1875-1884 (2012)
  12. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway. Akool el-S, Doller A, Müller R, Gutwein P, Xin C, Huwiler A, Pfeilschifter J, Eberhardt W. J Biol Chem 280 39403-39416 (2005)
  13. New and old treatment modalities in primary myelofibrosis. Cervantes F, Mesa R, Barosi G. Cancer J 13 377-383 (2007)
  14. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL. Oncogene 29 3335-3348 (2010)
  15. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms. Shi X, Mihaylova VT, Kuruvilla L, Chen F, Viviano S, Baldassarre M, Sperandio D, Martinez R, Yue P, Bates JG, Breckenridge DG, Schlessinger J, Turk BE, Calderwood DA. Proc Natl Acad Sci U S A 113 E4558-66 (2016)
  16. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Osman B, Doller A, Akool el-S, Holdener M, Hintermann E, Pfeilschifter J, Eberhardt W. Cell Signal 21 1806-1817 (2009)
  17. Structure-guided discovery of cyclin-dependent kinase inhibitors. Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V. Biopolymers 89 372-379 (2008)
  18. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Gellibert F, Fouchet MH, Nguyen VL, Wang R, Krysa G, de Gouville AC, Huet S, Dodic N. Bioorg Med Chem Lett 19 2277-2281 (2009)
  19. Regulatory T-cell depletion in the gut caused by integrin β7 deficiency exacerbates DSS colitis by evoking aberrant innate immunity. Zhang HL, Zheng YJ, Pan YD, Xie C, Sun H, Zhang YH, Yuan MY, Song BL, Chen JF. Mucosal Immunol 9 391-400 (2016)
  20. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Pharm Res 25 2427-2439 (2008)
  21. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Maier A, Peille AL, Vuaroqueaux V, Lahn M. Cell Oncol (Dordr) 38 131-144 (2015)
  22. A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands. Qin T, Barron L, Xia L, Huang H, Villarreal MM, Zwaagstra J, Collins C, Yang J, Zwieb C, Kodali R, Hinck CS, Kim SK, Reddick RL, Shu C, O'Connor-McCourt MD, Hinck AP, Sun LZ. Oncotarget 7 86087-86102 (2016)
  23. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5). Li X, Wang L, Long L, Xiao J, Hu Y, Li S. Bioorg Med Chem Lett 19 4868-4872 (2009)
  24. Crystal structures of apo and inhibitor-bound TGFβR2 kinase domain: insights into TGFβR isoform selectivity. Tebben AJ, Ruzanov M, Gao M, Xie D, Kiefer SE, Yan C, Newitt JA, Zhang L, Kim K, Lu H, Kopcho LM, Sheriff S. Acta Crystallogr D Struct Biol 72 658-674 (2016)
  25. Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Dewang PM, Kim DK. Bioorg Med Chem Lett 20 4228-4232 (2010)
  26. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK, Jung SH, Lee HS, Dewang PM. Eur J Med Chem 44 568-576 (2009)
  27. Computational studies of TGF-βRI (ALK-5) inhibitors: analysis of the binding interactions between ligand-receptor using 2D and 3D techniques. Araujo SC, Maltarollo VG, Honorio KM. Eur J Pharm Sci 49 542-549 (2013)
  28. Interactions between the circadian clock and TGF-β signaling pathway in zebrafish. Sloin HE, Ruggiero G, Rubinstein A, Smadja Storz S, Foulkes NS, Gothilf Y. PLoS One 13 e0199777 (2018)
  29. Pyrazolone based TGFbetaR1 kinase inhibitors. Guckian K, Carter MB, Lin EY, Choi M, Sun L, Boriack-Sjodin PA, Chuaqui C, Lane B, Cheung K, Ling L, Lee WC. Bioorg Med Chem Lett 20 326-329 (2010)
  30. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors. Kim DK, Choi JH, An YJ, Lee HS. Bioorg Med Chem Lett 18 2122-2127 (2008)
  31. Molecular docking analysis of curcumin analogues against kinase domain of ALK5. Kandagalla S, Sharath BS, Bharath BR, Hani U, Manjunatha H. In Silico Pharmacol 5 15 (2017)
  32. Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. Persson T, Yde CW, Rasmussen JE, Rasmussen TL, Guerra B, Issinger OG, Nielsen J. Org Biomol Chem 5 3963-3970 (2007)
  33. Structure, molecular dynamics simulation, and docking studies of Dictyostelium discoideum and human STRAPs. Kumar R, Saran S. J Cell Biochem 119 7177-7191 (2018)
  34. 2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling. Ciayadi R, Potdar M, Walton KL, Harrison CA, Kelso GF, Harris SJ, Hearn MT. Bioorg Med Chem Lett 21 5642-5645 (2011)
  35. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF. Oncol Lett 9 2442-2448 (2015)
  36. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5). Guo C, Zhang C, Li X, Li W, Xu Z, Bao L, Ding Y, Wang L, Li S. Bioorg Med Chem Lett 23 5850-5854 (2013)
  37. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase. Amada H, Sekiguchi Y, Ono N, Matsunaga Y, Koami T, Asanuma H, Shiozawa F, Endo M, Ikeda A, Aoki M, Fujimoto N, Wada R, Sato M. Bioorg Med Chem Lett 22 2024-2029 (2012)
  38. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats. Liu X, Yu M, Chen Y, Zhang J. Braz J Med Biol Res 49 e5388 (2016)
  39. Synthesis of Dihydrooxepino[3,2-c]Pyrazoles via Claisen Rearrangement and Ring-Closing Metathesis from 4-Allyloxy-1H-pyrazoles. Usami Y, Kohno A, Yoneyama H, Harusawa S. Molecules 23 E592 (2018)
  40. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles. Řezníčková E, Tenora L, Pospíšilová P, Galeta J, Jorda R, Berka K, Majer P, Potáček M, Kryštof V. Eur J Med Chem 127 632-642 (2017)
  41. Identification of protein binding partners of ALK-5 kinase inhibitors. Ciayadi R, Kelso GF, Potdar MK, Harris SJ, Walton KL, Harrison CA, Hearn MT. Bioorg Med Chem 21 6496-6500 (2013)
  42. Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole. Choodamani B, Cano Hernandez KG, Kumar S, Tony AM, Schiaffino Bustamante AY, Aguilera RJ, Schols D, Gopi Mohan C, Karki SS. Chem Biodivers 18 e2000800 (2021)
  43. Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors. Park MS, Park HJ, An YJ, Choi JH, Cha G, Lee HJ, Park SJ, Dewang PM, Kim DK. J Enzyme Inhib Med Chem 35 702-712 (2020)


Quick links